Oncolytics Biotech Aktie
WKN DE: A2JMW5 / ISIN: CA6823108759
11.06.2025 13:46:32
|
Oncolytics Biotech Announces Appointment Of Jared Kelly As CEO
(RTTNews) - Oncolytics Biotech Inc. (ONCY), Wednesday announced the appointment of Jared Kelly as Chief Executive Officer of the company.
Most recently, he played a crucial role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2 billion.
As part of the appointment, the company has awarded Kelly with an initial stock option for 2.85 million shares at C$0.57 vesting equally over three years, performance-based stock option of 1.9 million shares at C$0.57, and restricted stock units tied to certain potential transactions.
Concurrently, the clinical-stage biotechnology company stated that its lead drug, pelareorep, has achieved over 60 percent objective response rate, with survival rates higher than the control groups in metastatic pancreatic cancer trials.
In the pre-market hours, Oncolytics's stock is trading at $0.43, up 0.70 percent on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Oncolytics Biotech Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Oncolytics Biotech Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Oncolytics Biotech Inc Registered Shs | 1,38 | -2,82% |
|